0000000000280245

AUTHOR

A. Savarino

showing 7 related works from this author

Nab-paclitaxel (nab-P) in metastatic breast cancer (MBC) in elderly patients: A real life setting (NEREIDE study)

2018

Oncologymedicine.medical_specialtyOncologyPaclitaxel protein-boundbusiness.industryInternal medicineMedicineHematologybusinessReal life settingmedicine.diseaseMetastatic breast cancerNab-paclitaxelAnnals of Oncology
researchProduct

Kinetics of phenol removal by Nocardia species

1979

Phenol removal by pure cultures of Nocardia corallina was studied in a batch reacting system by estimating both the active biomass and the phenol concentration in the liquid during the experiments. A simple kinetic model was tested and the relative constants determined at 37°C.

ChromatographyKinetic modelChemistryKineticsBiomassGeneral MedicineNocardia speciesSettore MED/42 - Igiene Generale E ApplicataApplied Microbiology and BiotechnologyMicrobiologyNocardia corallinachemistry.chemical_compoundPure culturePhenolphenol Nocardia speciesBiotechnologyEuropean Journal of Applied Microbiology and Biotechnology
researchProduct

Inhibition of α-crystallin amyloid fibrils formation by carnosine

2008

SFM Scanning Force MicroscopyCD Circular DichroismThT Thioflavin THEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acidDSC Differential Scanning Calorimetry
researchProduct

The effect of Trehalose on the Alpha-Crystallin Aggregates

2006

researchProduct

Multicenter study of the eValuation of Eribulin (E) use in Sicily in metastatic breast cancer (MBC): A Prospective RegistrY (VESPRY trial)

2015

e12565 Background: Eribulin Mesylate is a non taxane microtubule dynamics inhibitor, approved for heavily-pretreated MBC patients (pts). Methods: This is a multicenter, prospective, single arm study for E-treatment of third line in pretreated MBC pts, conducted in 14 oncology centers in Sicily. All pts had received two previous chemotherapy regimens for MBC. Pts received E at 1.23 mg/m2 on days 1,8 every 3 weeks until progression. Primary Endpoints: overall response rate (ORR) according to the site of metastases and safety. Secondary objectives: Progression-free survival (PFS) and ORR according to different subtypes. PFS curve was estimated using the Kaplan-Meier method. Multivariable logi…

Eribulin MesylateGynecologyOncologyCancer Researchmedicine.medical_specialtyTaxaneMicrotubule dynamicsbusiness.industryHematologymedicine.diseaseMetastatic breast cancerSurgerychemistry.chemical_compoundOncologychemistryInternal medicineMedicinebusinessEribulinAnnals of Oncology
researchProduct

Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study

2017

Oncologymedicine.medical_specialty010405 organic chemistrybusiness.industrySettore MED/06 - Oncologia MedicabREast cancer In elDerly patiEntsHematology010402 general chemistrymedicine.disease01 natural sciencesMetastatic breast cancer0104 chemical sciencesBreast cancerOncologyInternal medicinemedicinebusinessNab-paclitaxel
researchProduct

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

2019

Background: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). Methods: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the …

OncologyEribulin Mesylatemedicine.medical_specialtymulticentreThird-line therapylcsh:RC254-282chemistry.chemical_compoundInternal medicinemedicineIn patienteribulin metastatic breast cancer multicentre prospective real world third lineeribulinthird lineOriginal Researchbusiness.industryreal worldprospectivemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMetastatic breast cancerSafety profileSurvival benefitOncologychemistryObservational studymetastatic breast cancerbusinessEribulinTherapeutic Advances in Medical Oncology
researchProduct